Archive

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by

  • Isofol Reports 58 % Overall Response Rate

    Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…

    by

  • Poadcast – “The Cancer Gene”

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…

    by
  • aside

    Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior…

    by
  • aside

    Isofol has participated in the Empowered Patient Podcast

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO…

    by
    0
  • aside

    Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by
  • aside

    First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • aside

    Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of…

    by
  • aside

    Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…

    by
  • aside

    Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the…

    by
  • aside

    Isofol presents a poster at ESMO 2018 Congress in Germany

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005;…

    by
  • aside

    New Chairman and extended board at Isofol Medical AB (publ)

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday…

    by
  • aside

    Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate),…

    by
  • aside

    DNB initiates monitoring of Isofol

    The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB.     For more information, please contact: Anders…

    by
  • aside

    Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology) in Chicago in June, Redeye brings…

    by
  • aside

    Isofol announces that an abstract with new research results has been published for this year’s ASCO congress in Chicago

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American…

    by